As of Friday close, Axsome Therapeutics Inc.’s (NASDAQ:AXSM) stock was up $1.53, moving up 2.21 percent to $70.78. The average number of shares traded per day over the past five days has been 595,400 shares. 2 times new highs have been achieved over the past 5 days, with a $1.18 gain in that time frame. In the last twenty days, the average volume was 831,225, while in the previous 50 days, it was 986,890.
Since last month, AXSM stock retreated -4.90%. Shares of the company fell to $67.52 on 08/14/23, the lowest level in the past month. A 52-week high of $91.29 was reached on 06/22/23 after having rallying from a 52-week low of $38.87. Since the beginning of this year, AXSM’s stock price has dropped by -8.23% or -$6.35, and marked a new high 8 times. However, the stock has declined by -22.47% since its 52-week high.
Valuation Metrics
The stock’s beta is 1.90. Besides these, the trailing price-to-sales (P/S) ratio of 18.54, the price-to-book (PB) ratio of 11.09.
Financial Health
In the three months ended June 29, Axsome Therapeutics Inc.’s quick ratio stood at 4.40, while its current ratio was 4.50, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.63, and the total debt-to-equity ratio was 0.63. On the profitability front, the trailing twelve-month gross margin is 91.00% percent. In the year ended June 29, EBITDA margin amounted to -340.62%, whereas operating margins totaled -95.20%. Based on annual data, AXSM earned $44.84 million in gross profit and brought in $50.04 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -88.20%. Return on equity (ROE) for the past 12 months was -112.20%.
In Axsome Therapeutics Inc.’s quarter-end financial report for June 29, it reported total debt of $176.82 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. AXSM’s revenue rose 81.11% to $94.58 million during the quarter, while net income inched up to $46.7 million. While analysts expected Axsome Therapeutics Inc. to report -$1.22 quarterly earnings, the actual figure was -$1.54 per share, beating the consensus estimate by -26.20%. During the quarter, the company generated -$62.0 million in EBITDA. The liabilities of Axsome Therapeutics Inc. were 332.83 million at the end of its most recent quarter ended June 29, and its total debt was $184.71 million. The value of shareholders’ equity is $47.19 million.
Technical Picture
This quick technical analysis looks at Axsome Therapeutics Inc.’s (AXSM) price momentum. With a historical volatility rate of 31.81%, the RSI 9-day stood at 43.97% on 18 August.
With respect to its five-day moving average, the current Axsome Therapeutics Inc. price is up by +1.70% percent or $1.18. At present, AXSM shares trade -5.80% below its 20-day simple moving average and +10.73% percent above its 100-day simple moving average. However, the stock is currently trading approximately -6.24% below its SMA50 and +56.77% above its SMA200.
Stochastic coefficient K was 22.91% and Stochastic coefficient D was 25.85%, while ATR was 3.06. Given the Stochastic reading of 29.06% for the 14-day period, the RSI (14) reading has been calculated as 43.99%. As of today, the MACD Oscillator reading stands at -0.51, while the 14-day reading stands at -1.74.
Analyst Ratings
BofA Securities upgraded its rating on Axsome Therapeutics Inc. (NASDAQ: AXSM) to a Neutral in a note to investors on August 08, 2023. The analysts firm previously had an Underperform rating on the stock.Axsome Therapeutics Inc. (AXSM) has been rated Buy by analysts. According to 0 brokerage firms, AXSM is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Axsome Therapeutics Inc. stock as buy, with 10 recommending it as overweight.
With a median target price of $107.26, the current consensus forecast for the stock is $81.00 – $180.00. Based on these forecasts, analysts predict Axsome Therapeutics Inc. (AXSM) will achieve an average price target of $115.63.
